Evidence map›Paper›PMID 33234243›Full record

ReviewInternational review of cell and molecular biology2020

TAM receptors and their ligand-mediated activation: Role in atherosclerosis.

Bishuang Cai, Canan Kasikara

Open access · greenAbstract readReview
In one paragraph

Review in International review of cell and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Mechanism of efferocytosis in atherosclerosis.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  8. The Role of TAM Receptors in Bone.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bishuang CaiDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: bishuang.cai@mssm.edu.
Canan KasikaraDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States.
Columbia University · USIcahn School of Medicine at Mount Sinai · US

Funding

MerTK in NASH-related liver fibrosisR00DK115778 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, BISHUANG · 2020 to 2022
$747k
NIDDK NIH HHS R00 DK115778
6 · The paper itself

Abstract

TAM family tyrosine kinase receptors including Tyro3, Axl, and MerTK are the key efferocytosis receptors presenting on antigen-presenting cell that mediate the clearance of apoptotic cells. They are thought to regulate inflammatory diseases by modulating inflammatory response and efferocytosis. Recent studies have revealed novel roles of TAM receptors in the biosynthesis of specialized pro-resolving mediators (SPMs) and inflammation resolution. In this chapter, we discuss the central roles of TAM signaling in atherosclerosis focusing on their regulation in efferocytosis and inflammation resolution and highlight the unique therapeutic potential of SPMs in blocking the progression of atherosclerosis.

Indexed as

AnimalsAtherosclerosisAxl Receptor Tyrosine Kinasec-Mer Tyrosine KinaseHumansLigandsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXL protein, humanAxl Receptor Tyrosine Kinasec-Mer Tyrosine KinaseLigandsMERTK protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesTYRO3 protein, humanAtherosclerosisEfferocytosisInflammation resolutionMerTK cleavageSpecialized pro-resolving mediatorsTAM

Identifiers

PMID33234243
PMCPMC7971185
OpenAlexW3092463200

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.